Current and emerging treatment options in triple-negative breast cancer
Triple-negative breast cancer is defined by the lack of estrogen receptor, progesterone receptor and HER2 expression with immunohistochemical analysis. Triplenegative breast cancers are poorly differentiated, characterized by high histological grade and occur at a younger age. Treatment options are...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2011-12-01
|
| Series: | Oncology Reviews |
| Subjects: | |
| Online Access: | http://www.oncologyreviews.org/index.php/or/article/view/43 |
| _version_ | 1797963085647970304 |
|---|---|
| author | Omer Dizdar Kadri Altundag |
| author_facet | Omer Dizdar Kadri Altundag |
| author_sort | Omer Dizdar |
| collection | DOAJ |
| description | Triple-negative breast cancer is defined by the lack of estrogen receptor, progesterone receptor and HER2 expression with immunohistochemical analysis. Triplenegative breast cancers are poorly differentiated, characterized by high histological grade and occur at a younger age. Treatment options are limited as these tumors are naturally resistant to existing targeted therapies, i.e., endocrine treatment and trastuzumab. An improved understanding of the biology of TNBC has led to evaluation of DNA-damaging chemotherapy drugs and targeted agents, including poly (ADP-ribose) polymerase inhibitors, epidermal growth factor receptor inhibitors, angiogenesis inhibitors, etc., in the treatment of TNBC. This review focuses on outlining the current and emerging treatment options in patients with triple-negative breast cancer. |
| first_indexed | 2024-04-11T01:22:49Z |
| format | Article |
| id | doaj.art-755372d6fca34731a35acf3b00bf3b9c |
| institution | Directory Open Access Journal |
| issn | 1970-5557 1970-5565 |
| language | English |
| last_indexed | 2024-04-11T01:22:49Z |
| publishDate | 2011-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Oncology Reviews |
| spelling | doaj.art-755372d6fca34731a35acf3b00bf3b9c2023-01-03T10:59:53ZengFrontiers Media S.A.Oncology Reviews1970-55571970-55652011-12-014110.4081/oncol.2010.538Current and emerging treatment options in triple-negative breast cancerOmer Dizdar0Kadri Altundag1Department of Medical Oncology, Hacettepe University Institute of Oncology, AnkaraDepartment of Medical Oncology, Hacettepe University Institute of Oncology, AnkaraTriple-negative breast cancer is defined by the lack of estrogen receptor, progesterone receptor and HER2 expression with immunohistochemical analysis. Triplenegative breast cancers are poorly differentiated, characterized by high histological grade and occur at a younger age. Treatment options are limited as these tumors are naturally resistant to existing targeted therapies, i.e., endocrine treatment and trastuzumab. An improved understanding of the biology of TNBC has led to evaluation of DNA-damaging chemotherapy drugs and targeted agents, including poly (ADP-ribose) polymerase inhibitors, epidermal growth factor receptor inhibitors, angiogenesis inhibitors, etc., in the treatment of TNBC. This review focuses on outlining the current and emerging treatment options in patients with triple-negative breast cancer.http://www.oncologyreviews.org/index.php/or/article/view/43Breast cancer - Triple-negative - Basal-like - Treatment |
| spellingShingle | Omer Dizdar Kadri Altundag Current and emerging treatment options in triple-negative breast cancer Oncology Reviews Breast cancer - Triple-negative - Basal-like - Treatment |
| title | Current and emerging treatment options in triple-negative breast cancer |
| title_full | Current and emerging treatment options in triple-negative breast cancer |
| title_fullStr | Current and emerging treatment options in triple-negative breast cancer |
| title_full_unstemmed | Current and emerging treatment options in triple-negative breast cancer |
| title_short | Current and emerging treatment options in triple-negative breast cancer |
| title_sort | current and emerging treatment options in triple negative breast cancer |
| topic | Breast cancer - Triple-negative - Basal-like - Treatment |
| url | http://www.oncologyreviews.org/index.php/or/article/view/43 |
| work_keys_str_mv | AT omerdizdar currentandemergingtreatmentoptionsintriplenegativebreastcancer AT kadrialtundag currentandemergingtreatmentoptionsintriplenegativebreastcancer |